Phaseline

Companies › Suzhou Junjing BioSciences

Suzhou Junjing BioSciences: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
WJ01024 tablets–Phase 1Intermediate- and High-risk Myelofibrosis (MF) Patients With SplenomegalyOct 2027
JS111 capsules (AP-L1898)
EGFR inhibitor
EGFRPhase 1NSCLCJul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06909136WJ01024 tabletsPhase 1Intermediate- and High-risk Myelofibrosis (MF) Patients With SplenomegalyOncologyOct 2027
NCT06940401JS111 capsules (AP-L1898)Phase 1NSCLCOncologyJul 2028

Targets

EGFR (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.